{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:59:42Z","timestamp":1785117582974,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharm Health Care Sci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Argatroban is an antithrombotic agent commonly used in the acute phase of cerebral infarction. Although the standard administration method is continuous infusion within the first 2 days only, many patients receive continuous intravenous infusion beyond day 3 owing to concerns of symptoms worsening during intermittent dosing, which may be insufficient given the short half-life of argatroban. However, evidence supporting the continuous intravenous infusion beyond day 3 remains limited. This study aimed to compare the safety and efficacy between continuous and intermittent argatroban administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients who received argatroban for acute cerebral infarction at Kyoto University Hospital between January 2019 and August 2021 were retrospectively evaluated. The patients were categorized based on actual treatment regimens into either the intermittent or continuous infusion group. Clinical characteristics, safety outcomes, and neurological status were then compared between the groups. The primary outcome was the incidence of bleeding events, and the secondary outcome was neurological status, as assessed using the manual muscle test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No clear difference in safety was observed between the two groups. The proportion of patients with a manual muscle test score of 10 significantly increased over time in the intermittent infusion group, whereas no such trend was observed in the continuous infusion group. Subgroup analysis by stroke type showed a similar increasing trend in all groups except the continuous infusion group with branch atheromatous disease, which is known to be associated with a high risk of early neurological deterioration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Continuous argatroban administration was not associated with an increased risk of bleeding events within the limitations of the current study, despite more intensive concomitant antithrombotic therapy. Although no clear neurological improvement was observed, continuous administration may represent a feasible treatment option in carefully selected patients; however, these findings should be interpreted with caution due to baseline imbalances and potential selection bias, warranting further prospective investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40780-026-00585-z","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T10:53:28Z","timestamp":1779965608000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and effects of continuous argatroban administration in acute cerebral infarction: a retrospective analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Machiko","family":"Hirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shigetsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Hira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takakuni","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsaku","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"585_CR1","doi-asserted-by":"publisher","unstructured":"Hacke W, Kaste M, Bluhmki E, Brozman M, D\u00e1valos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317\u201329. https:\/\/doi.org\/10.1056\/NEJMoa0804656.","DOI":"10.1056\/NEJMoa0804656"},{"key":"585_CR2","doi-asserted-by":"publisher","unstructured":"Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695\u2013703. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(10)60491-6\/abstract. https:\/\/doi.org\/10.1016\/S0140-6736(10)60491-6.","DOI":"10.1016\/S0140-6736(10)60491-6"},{"key":"585_CR3","doi-asserted-by":"publisher","unstructured":"Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1706442.","DOI":"10.1056\/NEJMoa1706442"},{"key":"585_CR4","doi-asserted-by":"publisher","unstructured":"Bath PM. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012;43(3):623\u20134. https:\/\/doi.org\/10.1161\/STROKEAHA.111.640557.","DOI":"10.1161\/STROKEAHA.111.640557"},{"key":"585_CR5","doi-asserted-by":"publisher","unstructured":"Barreto AD, Alexandrov AV, Lyden P, Lee J, Martin-Schild S, Shen L, et al. The argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study. Stroke. 2012;43(3):770\u20135. https:\/\/doi.org\/10.1161\/STROKEAHA.111.625574.","DOI":"10.1161\/STROKEAHA.111.625574"},{"key":"585_CR6","doi-asserted-by":"publisher","unstructured":"Berekashvili K, Soomro J, Shen L, Misra V, Chen PR, Blackburn S, et al. Safety and feasibility of argatroban, recombinant tissue plasminogen activator, and intra-arterial therapy in stroke (ARTSS-IA study). J Stroke Cerebrovasc Dis. 2018;27(12):3647\u201351. Available from: https:\/\/www.strokejournal.org\/article\/S1052-3057(18)30491-9\/abstract. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2018.08.036.","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.08.036"},{"key":"585_CR7","doi-asserted-by":"publisher","unstructured":"Barreto AD, Ford GA, Shen L, Pedroza C, Tyson J, Cai C, et al. Randomized, multicenter trial of ARTSS-2 (argatroban with recombinant tissue plasminogen activator for acute stroke). Stroke. 2017;48(6):1608\u201316. https:\/\/doi.org\/10.1161\/STROKEAHA.117.016720.","DOI":"10.1161\/STROKEAHA.117.016720"},{"key":"585_CR8","doi-asserted-by":"publisher","unstructured":"Zhang X, Zhong W, Xue R, Jin H, Gong X, Huang Y, et al. Argatroban in patients with acute ischemic stroke with early neurological deterioration: a randomized clinical trial. JAMA Neurol. 2024;81(2):118\u201325. Available from: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2813359.\u00a0https:\/\/doi.org\/10.1001\/jamaneurol.2023.5093.","DOI":"10.1001\/jamaneurol.2023.5093"},{"key":"585_CR9","doi-asserted-by":"publisher","unstructured":"Xu J, Xu X, Wang H, He L, Liu Q, Du Y, et al. Dual antiplatelet therapy plus argatroban prevents early neurological deterioration in branch atherosclerosis disease. Stroke. 2022;53(1):e19\u201320. https:\/\/doi.org\/10.1161\/STROKEAHA.121.036356.","DOI":"10.1161\/STROKEAHA.121.036356"},{"key":"585_CR10","doi-asserted-by":"publisher","unstructured":"Jeske WP, Fareed J, Hoppensteadt DA, Lewis B, Walenga JM. Pharmacology of argatroban. Expert Rev Hematol. 2010;3(5):527\u201339. https:\/\/doi.org\/10.1586\/ehm.10.53.","DOI":"10.1586\/ehm.10.53"},{"key":"585_CR11","doi-asserted-by":"publisher","unstructured":"Higuchi E, Uchiyama Y, Iizima M, Kitagawa K. A case of atherothrombotic cerebral infarction showing progressing stroke after discontinuation of a direct thrombin inhibitor (in Japanese). Jpn J Stroke. 2015;37:446\u201351. Available from: https:\/\/www.jstage.jst.go.jp\/article\/jstroke\/37\/6\/37_10328\/_article\/-char\/en. https:\/\/doi.org\/10.3995\/jstroke.10328.","DOI":"10.3995\/jstroke.10328"},{"key":"585_CR12","doi-asserted-by":"publisher","unstructured":"Kikui S, Sawa N, Nishiwaki T. Argatroban therapy (60 mg\/day) for 7 consecutive days improved neurological symptoms of progressing stroke due to severe stenosis of the internal carotid artery (in Japanese). Jpn J Stroke. 2010;32(5):482\u20135. Available from: https:\/\/www.jstage.jst.go.jp\/article\/jstroke\/32\/5\/32_5_482\/_article\/-char\/ja\/. https:\/\/doi.org\/10.3995\/jstroke.32.482.","DOI":"10.3995\/jstroke.32.482"},{"key":"585_CR13","doi-asserted-by":"publisher","unstructured":"Hasegawa T, Hashimoto T, Sada M, Kanata A, Kusunoki S. A case of embolic stroke with oscillating thrombus in the internal carotid artery associated with antiphospholipid antibody syndrome and complicated by systemic sclerosis (in Japanese). Neurosonology. 2014;17:145\u20137. Available from: https:\/\/www.jstage.jst.go.jp\/article\/neurosonology\/17\/3\/17_3_145\/_article\/-char\/ja\/.\u00a0https:\/\/doi.org\/10.2301\/neurosonology.17.145.","DOI":"10.2301\/neurosonology.17.145"},{"key":"585_CR14","doi-asserted-by":"publisher","unstructured":"Sunaga T, Higashino M, Kimura A, Baba Y, Tanioka T, Watanabe T, et al. Examination of the relationship between worsening symptoms and administration routes of argatroban in acute ischemic stroke patients (in Japanese). Yakugaku Zasshi. 2020;140(11):1373\u201380. Available from: https:\/\/www.jstage.jst.go.jp\/article\/yakushi\/140\/11\/140_20-00090\/_article\/-char\/ja\/.\u00a0https:\/\/doi.org\/10.1248\/yakushi.20-00090.","DOI":"10.1248\/yakushi.20-00090"},{"key":"585_CR15","doi-asserted-by":"publisher","unstructured":"Hoshino H, Takagi M, Yamamoto Y, Ishibashi Y, Terayama Y, Takeda H, et al. Neurological progression and clinical outcome of branch atheromatous disease (results from the J-BAD registry) (in Japanese). Rinsho Shinkeigaku. 2010;50(11):919\u201320. https:\/\/www.jstage.jst.go.jp\/article\/clinicalneurol\/50\/11\/50_11_919\/_article\/-char\/ja\/https:\/\/doi.org\/10.5692\/clinicalneurol.50.919","DOI":"10.5692\/clinicalneurol.50.919"},{"key":"585_CR16","doi-asserted-by":"publisher","unstructured":"Nakase T, Yamamoto Y, Takagi M, Japan Branch Atheromatous Disease Registry Collaborators. The impact of diagnosing branch atheromatous disease for predicting prognosis. J Stroke Cerebrovasc Dis. 2015;24(10):2423\u20138. Available from: https:\/\/www.strokejournal.org\/article\/S1052-3057(15)00386-9\/abstract. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2015.06.044.","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.06.044"},{"key":"585_CR17","doi-asserted-by":"publisher","unstructured":"Deguchi I, Hayashi T, Kato Y, Nagoya H, Ohe Y, Fukuoka T, et al. Treatment outcomes of tissue plasminogen activator infusion for branch atheromatous disease. J Stroke Cerebrovasc Dis. 2013;22(7):e168\u2013e172. Available from: https:\/\/www.strokejournal.org\/article\/S1052-3057(12)00356-4\/abstract. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2012.10.012.","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.10.012"},{"key":"585_CR18","doi-asserted-by":"publisher","unstructured":"Aitkens S, Lord J, Bernauer E, Fowler WM Jr, Lieberman JS, Berck P. Relationship of manual muscle testing to objective strength measurements. Muscle Nerve. 1989;12(3):173\u20137. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.880120302. https:\/\/doi.org\/10.1002\/mus.880120302.","DOI":"10.1002\/mus.880120302"},{"key":"585_CR19","doi-asserted-by":"publisher","unstructured":"Rahman H, Khan SU, Nasir F, Hammad T, Meyer MA, Kaluski E. Optimal duration of aspirin plus clopidogrel after ischemic stroke or transient ischemic attack. Stroke. 2019;50(4):947\u201353. https:\/\/doi.org\/10.1161\/STROKEAHA.118.023978.","DOI":"10.1161\/STROKEAHA.118.023978"},{"key":"585_CR20","doi-asserted-by":"publisher","unstructured":"Bath PM, Woodhouse LJ, Appleton JP, Beridze M, Christensen H, Dineen RA, et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. Lancet. 2018;391(10123):850\u20139. Available from: https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(17)32849-0\/fulltext. https:\/\/doi.org\/10.1016\/S0140-6736(17)32849-0.","DOI":"10.1016\/S0140-6736(17)32849-0"},{"key":"585_CR21","doi-asserted-by":"publisher","unstructured":"Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A. Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005;36(11):2415\u201320. https:\/\/doi.org\/10.1161\/01.STR.0000185730.50480.e7.","DOI":"10.1161\/01.STR.0000185730.50480.e7"},{"key":"585_CR22","doi-asserted-by":"publisher","unstructured":"Caplan LR. Intracranial branch atheromatous disease: a neglected, understudied, and underused concept. Neurology. 1989;39(9):1246\u201350. https:\/\/doi.org\/10.1212\/WNL.39.9.1246.","DOI":"10.1212\/WNL.39.9.1246"},{"key":"585_CR23","unstructured":"Adachi T, Takagi M. The clinical differences between lacunar infarction and branch atheromatous disease (in Japanese). Nihon Rinsho. 2006;64 Suppl 8:155\u20139. Available from: https:\/\/mol.medicalonline.jp\/library\/journal\/abstract?GoodsID=ag6niria\/2006\/0064s8\/032&name=0155-0159j&UserID=133.3.201.164."},{"key":"585_CR24","doi-asserted-by":"publisher","unstructured":"Yamamoto Y, Ohara T, Hamanaka M, Hosomi A, Tamura A, Akiguchi I. Characteristics of intracranial branch atheromatous disease and its association with progressive motor deficits. J Neurol Sci. 2011;304(1\u20132):78\u201382. Available from: https:\/\/www.jns-journal.com\/article\/S0022-510X(11)00061-X\/abstract. https:\/\/doi.org\/10.1016\/j.jns.2011.02.006.","DOI":"10.1016\/j.jns.2011.02.006"}],"container-title":["Journal of Pharmaceutical Health Care and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40780-026-00585-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00585-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40780-026-00585-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:29:15Z","timestamp":1785115755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40780-026-00585-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["585"],"URL":"https:\/\/doi.org\/10.1186\/s40780-026-00585-z","relation":{},"ISSN":["2055-0294"],"issn-type":[{"value":"2055-0294","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Ethics Committee of the Kyoto University Graduate School of Medicine, School of Medicine, and Faculty of Medicine Hospital on September 10, 2021 (approval number: R3165) and was performed in accordance with the Ethical Guidelines for Life Science and Medical Research Involving Human Subjects. Informed consent was obtained from all patients after providing an explanation of the treatment purpose, potential risks, and benefits.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"67"}}